Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company whose news flow centers on cardiometabolic and neurological drug development, regulatory interactions and strategic collaborations. The company describes a mission of pioneering medicines that transform patients’ lives, supported by its Genome5000™ genomics platform, which identified more than 100 protein targets with therapeutic potential across multiple diseases.
News about Lexicon frequently highlights clinical data and conference presentations for sotagliflozin, an oral SGLT2 and SGLT1 inhibitor studied in approximately 20,000 patients with heart failure, diabetes and chronic kidney disease. Recent updates include results in heart failure with preserved ejection fraction, ongoing enrollment in the SONATA-HCM Phase 3 study for hypertrophic cardiomyopathy, and work toward regulatory pathways for ZYNQUISTA® in type 1 diabetes.
Investors and healthcare observers can also follow developments in pilavapadin (LX9211) for diabetic peripheral neuropathic pain, where Lexicon has reported Phase 2 and Phase 2b data and End-of-Phase 2 FDA discussions, as well as LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders licensed to Novo Nordisk. Company news includes licensing milestones, financial results, participation in major healthcare conferences and policy-focused initiatives such as a chronic pain roundtable and white paper on non-opioid treatments.
This LXRX news page aggregates these updates in one place, covering earnings releases, pipeline milestones, regulatory announcements, scientific publications and partnership news drawn from Lexicon’s public statements and SEC filings.
Lexicon Pharmaceuticals announced its New Drug Application (NDA) for sotagliflozin has been accepted for review by the FDA. This investigational drug, a dual SGLT1 and SGLT2 inhibitor, targets heart failure and is backed by the SOLOIST-WHF and SCORED Phase 3 studies with nearly 12,000 participants. The FDA set a standard review timeline for May 2023. Lexicon aims for a broad indication covering heart failure patients, with positive trial outcomes supporting its potential to reduce cardiovascular risks.
Lexicon Pharmaceuticals (LXRX) announced positive top-line results from the Phase 2 RELIEF-DPN-1 study of LX9211 for painful diabetic neuropathy. The drug achieved the primary endpoint, with a significant decrease in average daily pain scores compared to placebo, particularly at low doses. The study involved 319 patients and highlighted LX9211's potential new mechanism of action. While adverse events were more common in treatment groups, they were mostly mild. LX9211 has received Fast Track designation from the FDA, enhancing its development prospects.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that its CEO, Lonnel Coats, will present at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 10:00 a.m. ET. A webcast of the event will be accessible on Lexicon's website, with an archived version available for two weeks. Lexicon focuses on pioneering biopharmaceuticals, having studied nearly 5,000 genes to identify over 100 protein targets for therapeutic development. The company has advanced one medication to market and has several candidates in various stages of development for conditions such as heart failure and diabetes.
Lexicon Pharmaceuticals (LXRX) has resubmitted a New Drug Application (NDA) to the FDA for sotagliflozin, targeting heart failure treatment. The NDA, based on the SOLOIST-WHF and SCORED Phase 3 trials, aims to address significant medical needs. The FDA will review the submission within a 60-day period to decide on its completeness. The trials demonstrated the efficacy of sotagliflozin, achieving their primary endpoints, which involved reductions in cardiovascular events among patients with diabetes and heart failure.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q1 2022 financial results, showing a net loss of $23.5 million, or $0.16 per share, compared to a loss of $21.0 million, or $0.15 per share in Q1 2021. The company plans to resubmit its New Drug Application for sotagliflozin for heart failure treatment, supported by a $150 million loan facility. Significant reductions in major adverse cardiovascular events were noted in sotagliflozin trials. Top-line results for LX9211 studies are expected this year.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will announce its Q1 2022 financial results on May 5, 2022, prior to market opening. A conference call will follow at 8:00 a.m. ET for discussing the results and offering a business update. Lexicon focuses on innovative medicines targeting over 100 therapeutic proteins identified through its Genome5000™ program. The company has progressed one drug to market and has a pipeline in various stages of development for conditions including heart failure and diabetes.
Lexicon Pharmaceuticals announced that Jeffrey L. Wade, President and CFO, will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:45 a.m. ET. The event will be available via webcast on Lexicon's website, with an archived version accessible for two weeks post-event.
Lexicon focuses on pioneering medicines through its Genome5000™ program, identifying therapeutic targets across various diseases. The company has one medicine on the market and a pipeline in clinical and preclinical stages, including treatments for heart failure, neuropathic pain, and diabetes.
Lexicon Pharmaceuticals (LXRX) welcomes new heart failure management guidelines from the AHA, ACC, and HFSA. The guidelines recommend SGLT2 inhibitors as a first-line treatment for heart failure (HF) across various categories, strengthening the therapeutic landscape for this condition. Notably, they highlight the need for improved medical therapy optimization during hospitalizations. Lexicon's sotagliflozin is recognized for its unique mechanism, with clinical trials validating its efficacy. The guidelines replace earlier standards and are expected to boost SGLT2 inhibitor adoption.
Lexicon Pharmaceuticals announced significant findings from the SCORED Phase 3 clinical trial for sotagliflozin, presented at the American College of Cardiology’s 71st Annual Scientific Session. The analysis, involving 10,584 patients with type 2 diabetes and chronic kidney disease, revealed a 21% reduction in major adverse cardiovascular events (MACE) in patients with cardiovascular disease and a 26% reduction in those without. The results underscore sotagliflozin's potential in reducing cardiovascular death, myocardial infarction, and stroke, reinforcing its therapeutic significance.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced a late-breaking presentation at the American College of Cardiology’s 71st Annual Scientific Session. Dr. Deepak L. Bhatt will present a secondary analysis of sotagliflozin data from the SCORED Phase 3 trial on April 2, 2022. The analysis will focus on the reduction of cardiovascular death, myocardial infarction, and stroke. Sotagliflozin is approved in the EU for type 1 diabetes. Despite its approval, commercial launch in the U.S. is pending. For more details, visit Lexicon's website.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
